Deferoxamine (DFO) has been in use for half a century as a Food and Drug Administration-approved iron chelator, but recent studies indicate a variety of properties that could expand this drug's application into the fields of tissue and regenerative engineering. DFO has been implicated as an angiogenic agent in studies on ischemia, wound healing, and bone regeneration because of its ability to upregulate hypoxia-inducible factor-1 alpha (HIF-1α) and other key downstream angiogenic factors. DFO has also demonstrated antioxidant capabilities unrelated to its iron-chelating properties, making it a potential modulator of the oxidative stress involved in the inflammation response. Together, these properties make DFO a potential bioactive molecule to promote wound healing and enhance tissue integration of biomaterials in vivo. Impact Statement Deferoxamine (DFO) is approved by the Food and Drug Administration as an iron chelator and is been used to treat iron overload. Recent studies indicate that DFO may have important applications in the growing field of tissue regeneration because of its unique properties of downregulating inflammation while promoting vascularization, thereby enhancing wound healing in vivo.

中文翻译：

---

去铁胺：一种用于组织再生的血管生成和抗氧化分子。

去铁胺（DFO）作为食品和药物管理局批准的铁螯合剂已经使用了半个世纪，但最近的研究表明，多种特性可以将该药物的应用扩展到组织和再生工程领域。由于DFO具有上调缺氧诱导因子1α（HIF-1α）和其他关键下游血管生成因子的能力，因此已被认为是缺血，伤口愈合和骨再生研究中的一种血管生成剂。DFO还显示了与其铁螯合特性无关的抗氧化剂功能，使其成为炎症反应中涉及的氧化应激的潜在调节剂。总之，这些特性使DFO成为潜在的生物活性分子，可以促进伤口愈合并增强体内生物材料的组织整合。影响声明去铁胺（DFO）已获得美国食品和药物管理局（FDA）的认可，可作为铁螯合剂，并用于治疗铁超载。最近的研究表明，DFO可能在组织再生的增长领域中具有重要的应用，因为它独特的特性是在促进血管生成的同时下调炎症，从而增强体内伤口的愈合。